GNLX MEXC RealStocks
Own real GNLX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 06:45:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Genelux Corporation (GNLX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.23, with a market capitalization of $96.13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.77 to $5.89. This page covers its latest market performance, valuation, price trends and company information.
$96.13M | |
$2.00 | |
$2.29 | |
$1.99 | |
$2.00 | |
643.54K | |
334.16K | |
-- | |
$5.89 | |
$1.77 | |
-- | |
2026-06-30 |
Genelux Corporation (GNLX) last closed at $2.23 as of 2026-11-18 23:06:00, up 12.00% ($0.24) from the previous close of $2.00.
During the latest regular trading session, GNLX traded between $1.99 and $2.29, with a volume of 643.54K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Genelux Corporation (GNLX) moved from $1.95 to $2.23, representing a gain of 14.41% ($0.28).
The stock traded between $1.81 and $2.29 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 290.55 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 11.2%
GNLX is currently trading at $2.23, placing it 11.2% of the way from its 52-week low of $1.77 to its 52-week high of $5.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 26 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Genelux Corporation (GNLX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GNLX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between GNLX shares and USD.
GNLX Shares to USD
1.00 GNLX shares = 2.231 USD
Calculations are estimates based on the latest available price and are for reference only.